Research article
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
Sebastian Schneeweiss, Stephen B. Soumerai, Robert J. Glynn, Malcolm Maclure, Colin Dormuth and Alexander M. Walker
CMAJ March 19, 2002 166 (6) 737-745;
Sebastian Schneeweiss
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Stephen B. Soumerai
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Robert J. Glynn
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Malcolm Maclure
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Colin Dormuth
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Alexander M. Walker
From the *Department of Epidemiology, Harvard School of Public Health, Boston, Mass.; the †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ‡Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass.; the §Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.; the ¶Department of Biostatistics, Harvard School of Public Health, Boston, Mass.; and Pharmacare, Ministry of Health, Victoria, BC
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
Sebastian Schneeweiss, Stephen B. Soumerai, Robert J. Glynn, Malcolm Maclure, Colin Dormuth, Alexander M. Walker
CMAJ Mar 2002, 166 (6) 737-745;
Jump to section
Related Articles
Cited By...
- Impact of Restrictive Prescription Plans on Heart Failure Medication Use
- Outcomes-Based Drug Coverage in British Columbia
- How Do Incentive-Based Formularies Influence Drug Selection And Spending For Hypertension?
- Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid
- Rethinking prescribing in the United States
- Pricing Drugs
- Whither Seniors' Pharmacare: Lessons From (And For) Canada
- Reference-based refinements
- Pharmaceutical cost containment with reference-based pricing: time for refinements
- Reference drug pricing
- Reference drug pricing
- Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia